Search Results - "Fokkink, Willem Jan R."

Novel approach to monitor intravenous immunoglobulin pharmacokinetics in humans using polymorphic determinants in IgG1 constant domains by Tilburg, Sander J., Jacobs, Bart C., Ooijevaar‐de Heer, Pleuni, Fokkink, Willem‐Jan R., Huizinga, Ruth, Vidarsson, Gestur, Rispens, Theo

“…Clinical efficacy of intravenous immunoglobulin treatment (IVIg) is related to its pharmacokinetic (PK) profile. Its usual evaluation, by measuring serum total…”
Get full text

Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy by Kuitwaard, Krista, Doorn, Pieter A., Bengrine, Thiziri, Rijs, Wouter, Baas, Frank, Nagelkerke, Sietse Q., Kuijpers, Taco W., Fokkink, Willem‐Jan R., Bunschoten, Carina, Broers, Merel C., Willemsen, Sten P., Jacobs, Bart C., Huizinga, Ruth

“…Background and purpose Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a clinical and electrophysiological heterogeneous immune‐mediated…”
Get full text

Clinical relevance of serum antibodies to GD1b in immune‐mediated neuropathies by Taams, Noor E., Notermans, Nicolette C., Fokkink, Willem‐Jan R., Tio‐Gillen, Anne P., Huizinga, Ruth, Schreurs, Marco W. J., Jacobs, Bart C.

“…Antibodies to the ganglioside GD1b have been reported in various forms of immune‐mediated neuropathy, but their clinical relevance for diagnosis and prognosis…”
Get full text

Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy by Kuitwaard, Krista, Fokkink, Willem‐Jan R., Brusse, Esther, Vrancken, Alexander F. J. E., Eftimov, Filip, Notermans, Nicolette C., van der Kooi, Anneke J., Merkies, Ingemar S. J., Jacobs, Bart C., van Doorn, Pieter A.

“…Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients treated with intravenous immunoglobulin (IVIg) usually start with a standard dosage…”
Get full text

Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G by Fokkink, Willem Jan R, Falck, David, Santbergen, Tom C M, Huizinga, Ruth, Wuhrer, Manfred, Jacobs, Bart C

“…Intravenous immunoglobulin (IVIg) products from different pharmaceutical companies vary in composition, in part because of the selected blood donors and…”
Get full text

Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study) by Kuitwaard, Krista, Fokkink, Willem‐Jan R., Brusse, Esther, Vrancken, Alexander F. J. E., Eftimov, Filip, Notermans, Nicolette C., van der Kooi, Anneke J., Merkies, Ingemar S. J., Jacobs, Bart C., van Doorn, Pieter A.

“…High peak levels of serum IgG may not be needed for maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with intravenous…”
Get full text

Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome by Fokkink, Willem-Jan R, Walgaard, Christa, Kuitwaard, Krista, Tio-Gillen, Anne P, van Doorn, Pieter A, Jacobs, Bart C

“…There is an urgent need for biomarkers to monitor treatment efficacy and anticipate outcome in patients with Guillain-Barré syndrome (GBS). To assess whether…”
Get more information

Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS by Fokkink, Willem‐Jan R., Haarman, Annechien E. G., Tio‐Gillen, Anne P., Rijs, Wouter, Huizinga, Ruth, Doorn, Pieter A., Jacobs, Bart C.

“…Treatment of Guillain‐Barré syndrome with a standard course of high‐dose intravenous immunoglobulin (IVIg) results in a variable clinical recovery which is…”
Get full text

Could Albumin be a Biomarker to Monitor the Effect of Intravenous Immunoglobulin on Guillain-Barré Syndrome?-Reply by Fokkink, Willem-Jan R, Jacobs, Bart C

Get more information

IgG Fc N‑Glycosylation in Guillain–Barré Syndrome Treated with Immunoglobulins by Fokkink, Willem-Jan R, Selman, Maurice H. J, Dortland, Juliette R, Durmuş, Büşra, Kuitwaard, Krista, Huizinga, Ruth, van Rijs, Wouter, Tio-Gillen, Anne P, van Doorn, Pieter A, Deelder, André M, Wuhrer, Manfred, Jacobs, Bart C

“…Intravenous immunoglobulin (IVIg) is the treatment of choice for Guillain–Barré syndrome (GBS), an immune-mediated peripheral neuropathy causing rapidly…”
Get full text

Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain–Barré Syndrome by Fokkink, Willem Jan R., van Tilburg, Sander J., de Winter, Brenda C. M., Sassen, Sebastiaan D. T., van Doorn, Pieter A., Koch, Birgit C. P., Jacobs, Bart C.

“…Background and Objective Intravenous immunoglobulin (IVIg) at a standard dosage is the treatment of choice for Guillain–Barré syndrome. The pharmacokinetics,…”
Get full text

Innate Immunity to Campylobacter jejuni in Guillain-Barré Syndrome by Huizinga, Ruth, van den Berg, Bianca, van Rijs, Wouter, Tio-Gillen, Anne P., Fokkink, Willem Jan R., Bakker-Jonges, Liesbeth E., Geleijns, Karin, Samsom, Janneke N., van Doorn, Pieter A., Laman, Jon D., Jacobs, Bart C.

“…Objective Guillain‐Barré syndrome (GBS) is a postinfectious neuropathy most frequently caused by Campylobacter jejuni. Lipo‐oligosaccharides (LOS), expressed…”
Get full text

IVIg‐induced plasmablasts in patients with Guillain‐Barré syndrome by Brem, Maarten D., Jacobs, Bart C., Rijs, Wouter, Fokkink, Willem Jan R., Tio‐Gillen, Anne P., Walgaard, Christa, Doorn, Pieter A., IJspeert, Hanna, Burg, Mirjam, Huizinga, Ruth

“…Objective The Guillain–Barré syndrome (GBS) is an acute, immune‐mediated disease of peripheral nerves. Plasmablasts and plasma cells play a central role in GBS…”
Get full text

IVI g‐induced plasmablasts in patients with Guillain‐Barré syndrome by Brem, Maarten D., Jacobs, Bart C., van Rijs, Wouter, Fokkink, Willem Jan R., Tio‐Gillen, Anne P., Walgaard, Christa, van Doorn, Pieter A., IJspeert, Hanna, van der Burg, Mirjam, Huizinga, Ruth

“…Abstract Objective The Guillain–Barré syndrome ( GBS ) is an acute, immune‐mediated disease of peripheral nerves. Plasmablasts and plasma cells play a central…”
Get full text

Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVI g or the clinical course of GBS by Fokkink, Willem‐Jan R., Haarman, Annechien E. G., Tio‐Gillen, Anne P., Rijs, Wouter, Huizinga, Ruth, Doorn, Pieter A., Jacobs, Bart C.

“…Treatment of Guillain‐Barré syndrome with a standard course of high‐dose intravenous immunoglobulin (IVIg) results in a variable clinical recovery which is…”
Get full text

Innate I mmunity to C ampylobacter jejuni in G uillain‐ B arré S yndrome by Huizinga, Ruth, van den Berg, Bianca, van Rijs, Wouter, Tio‐Gillen, Anne P., Fokkink, Willem Jan R., Bakker‐Jonges, Liesbeth E., Geleijns, Karin, Samsom, Janneke N., van Doorn, Pieter A., Laman, Jon D., Jacobs, Bart C.

“…Objective Guillain‐Barré syndrome (GBS) is a postinfectious neuropathy most frequently caused by Campylobacter jejuni . Lipo‐oligosaccharides (LOS), expressed…”
Get full text